Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Riedl Jakob |
** = Publikationen gelistet in SCI/SSCI/Pubmed
2022
Originalarbeit (Zeitschrift)
** Barth, DA; Stanzer, S; Spiegelberg, JA; Bauernhofer, T; Absenger, G; Szkandera, J; Gerger, A; Smolle, MA; Hutterer, GC; Ahyai, SA; Madl, T; Posch, F; Riedl, JM; Klec, C; Jost, PJ; Kargl, J; Stradner, MH; Pichler, M
Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Front Immunol. 2022; 13: 840207
Doi: 10.3389/fimmu.2022.840207
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Gressenberger, P; Posch, F; Pechtold, M; Gütl, K; Muster, V; Jud, P; Riedl, J; Silbernagel, G; Kolesnik, E; Schmid, J; Raggam, RB; Brodmann, M; Gary, T
Lipoprotein(a) and Pulmonary Embolism Severity-A Retrospective Data Analysis.
Front Cardiovasc Med. 2022; 9: 808605
Doi: 10.3389/fcvm.2022.808605
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Maisel, F; Smolle, MA; Mollnar, S; Riedl, JM; Barth, DA; Seles, M; Terbuch, A; Rossmann, CH; Eisner, F; Mannweiler, S; Hutterer, G; Zigeuner, R; Pummer, K; Smolle-Jüttner, FM; Lindenmann, J; Stotz, M; Gerger, A; Jost, PJ; Bauernhofer, T; Pichler, M; Posch, F
Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis.
Clin Genitourin Cancer. 2022; 20(4):344-353
Doi: 10.1016/j.clgc.2022.03.010
Web of Science
PubMed
FullText
FullText_MUG
** Mischinger, J; Schöllnast, H; Zurl, H; Geyer, M; Fischereder, K; Adelsmayr, G; Igrec, J; Fritz, G; Merdzo-Hörmann, M; Elstner, J; Schmid, J; Triebl, A; Trimmel, V; Reiter, C; Steiner, J; Rosenlechner, D; Seles, M; Pichler, GP; Pichler, M; Riedl, J; Schöpfer-Schwab, S; Strobl, J; Hutterer, GC; Zigeuner, R; Pummer, K; Augustin, H; Ahyai, S; Mannweiler, S; Fuchsjäger, M; Talakic, E
Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naïve and previous negative biopsy patients.
Front Surg. 2022; 9: 1013389
Doi: 10.3389/fsurg.2022.1013389
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Prinz, F; Jonas, K; Balihodzic, A; Klec, C; Reicher, A; Barth, DA; Riedl, J; Gerger, A; Kiesslich, T; Mayr, C; Rinner, B; Kargl, J; Pichler, M
MicroRNA mimics can distort physiological microRNA effects on immune checkpoints by triggering an antiviral interferon response.
RNA Biol. 2022; 19(1):1305-1315
Doi: 10.1080/15476286.2022.2152978
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Schwarzenbacher, E; Moik, F; Horvath, L; Gantschnigg, A; Renneberg, F; Posch, F; Barth, DA; Stotz, M; Pichler, M; Hatzl, S; Fandler-Höfler, S; Gressenberger, P; Gary, T; Jost, PJ; Greil, R; Ay, C; Djanani, A; Gerger, A; Schlick, K
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Thromb Haemost. 2022; 122(4):633-645
Doi: 10.1055/a-1548-4847
Web of Science
PubMed
FullText
FullText_MUG
** Schlintl, V; Huemer, F; Rinnerthaler, G; Melchardt, T; Winder, T; Reimann, P; Riedl, J; Amann, A; Eisterer, W; Romeder, F; Piringer, G; Ilhan-Mutlu, A; Woll, E; Greil, R; Weiss, L
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort
BMC CANCER. 2022; 22(1): 51
Doi: 10.1186/s12885-021-09115-6
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Moik, F; Riedl, J; Barth, D; Chan, WSE; Wiedemann, S; Holler, C; Fuereder, T; Jost, P; Pabinger, I; Preusser, M; Ay, C
Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors
BLOOD. 2022; 140: 1250-1251.
Doi: 10.1182/blood-2022-160087
[Oral Communication]
Web of Science
FullText
FullText_MUG
** Riedl, JM; Barth, D; Steinlechner, S; Moik, F; Posch, F; Schlintl, V; Mayer, MC; Sandner, AM; Berton, F; Koch, L; John, N; Wurm, R; Pichler, M; Absenger, G; Jost, PJ; Wohlkonig, C; Richtig, E; Winder, T; Gerger, A; Terbuch, A
Early CRP Kinetics after Initiation of Immune Checkpoint Inhibitors is a predictive Biomarker for Treatment Response independent of the Tumor Antity
ONCOL RES TREAT. 2022; 45(SUPPL 2):228-228.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien.
[Poster]
Web of Science
** Schranz, A; Sternad, C; Mischinger, HJ; Wagner, D; Jost, PJ; Riedl, J; Wolfler, A; Pieber, T; Sourij, H; Aberer, F
Incidence of diabetes and its impact on survival after pancreatic tumor surgery - a retrospective data analysis
WIEN KLIN WOCHENSCHR. 2022; 134(SUPPL 4):258-259.-Jahrestagung der Österreichischen Diabetesgesellschaft ;
[Poster]
Web of Science
2021
Originalarbeit (Zeitschrift)
** Barth, DA; Sareban, N; Lindner, AK; Daller, LAJ; Matzhold, EM; Hutterer, G; Smolle, M; Mischinger, J; Riedl, JM; Seles, M; Mannweiler, S; Bauernhofer, T; Pummer, K; Pichler, R; Zigeuner, R; Schlenke, P; Pichler, M
Prognostic relevance of ABO blood group system in non-metastatic renal cell carcinoma: An analysis of two independent European cohorts with long-term follow-up.
Urol Oncol. 2021; 39(10):736.e9-736.e16
Doi: 10.1016/j.urolonc.2021.06.005
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Hatzl, S; Kalmar, P; Posch, F; Riedl, JM; Beham-Schmid, C; Prochazka, K; Greinix, H; Schwarz, T; Gstettner, C; Neumeister, P; Schulz, E
Prognostic Value of Baseline and Interim Positron Emission Tomography Markers in Diffuse Large B-cell Lymphoma Patients: A Real-world Perspective.
Hemasphere. 2021; 5(8): e621
Doi: 10.1097/HS9.0000000000000621
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Müller, M; Posch, F; Kiem, D; Barth, D; Horvath, L; Stotz, M; Schaberl-Moser, R; Pichler, M; Greil, R; Jost, PJ; Seeber, A; Amann, A; Schlick, K; Gerger, A; Riedl, JM
Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.
Ther Adv Med Oncol. 2021; 13: 17588359211039930
Doi: 10.1177/17588359211039930
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Posch, F; Prinz, F; Balihodzic, A; Mayr, C; Kiesslich, T; Klec, C; Jonas, K; Barth, DA; Riedl, JM; Gerger, A; Pichler, M
MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms.
Cancers (Basel). 2021; 13(16):
Doi: 10.3390/cancers13163996
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Hasenleithner, SO; Pregartner, G; Scheipner, L; Posch, F; Groller, K; Kashofer, K; Jahn, SW; Bauernhofer, T; Pichler, M; Stöger, H; Berghold, A; Hoefler, G; Speicher, MR; Heitzer, E; Gerger, A
Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial.
Ther Adv Med Oncol. 2021; 13:1758835920987658
Doi: 10.1177/1758835920987658
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, DA; Rossmann, CH; Stotz, M; Schaberl-Moser, R; Pichler, M; Stöger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Eur J Cancer. 2021; 151: 3-13.
Doi: 10.1016/j.ejca.2021.03.040
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Scheipl, S; Brcic, I; Moser, T; Fischerauer, S; Riedl, J; Bergovec, M; Smolle, M; Posch, F; Gerger, A; Pichler, M; Stoeger, H; Leithner, A; Heitzer, E; Liegl-Atzwanger, B; Szkandera, J
Molecular profiling of soft-tissue sarcomas with FoundationOne® Heme identifies potential targets for sarcoma therapy: a single-centre experience.
Ther Adv Med Oncol. 2021; 13:17588359211029125
Doi: 10.1177/17588359211029125
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Scheipner, L; Smolle, MA; Barth, D; Posch, F; Stotz, M; Pichler, M; StÖger, H; Gerger, A; Riedl, JM
The AST/ALT Ratio Is an Independent Prognostic Marker for Disease-free Survival in Stage II and III Colorectal Carcinoma.
Anticancer Res. 2021; 41(1):429-436
Doi: 10.21873/anticanres.14792
Web of Science
PubMed
FullText
FullText_MUG
** Smolle, MA; Herbsthofer, L; Granegger, B; Goda, M; Brcic, I; Bergovec, M; Scheipl, S; Prietl, B; Pichler, M; Gerger, A; Rossmann, C; Riedl, J; Tomberger, M; López-García, P; El-Heliebi, A; Leithner, A; Liegl-Atzwanger, B; Szkandera, J
T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study.
Br J Cancer. 2021; 125(5):717-724
Doi: 10.1038/s41416-021-01456-0
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Fallbericht
** Schmid, J; Prattes, J; Kaufmann-Bühler, AK; Riedl, JM
Sampling site matters when testing for COVID-19 after total laryngectomy: a case report.
Wien Klin Wochenschr. 2021; 133(7-8):416-417
Doi: 10.1007/s00508-021-01826-x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2020
Originalarbeit (Zeitschrift)
** Barth, DA; Brenner, C; Riedl, JM; Prinz, F; Klocker, EV; Schlick, K; Kornprat, P; Lackner, K; Stöger, H; Stotz, M; Gerger, A; Pichler, M
External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients.
Cancer Med. 2020; 9(15):5473-5479
Doi: 10.1002/cam4.3233
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Bianconi, D; Herac, M; Posch, F; Schmeidl, M; Unseld, M; Kieler, M; Brettner, R; Mullauer, L; Riedl, J; Gerger, A; Scheithauer, W; Prager, G
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC.
THER ADV MED ONCOL. 2020; 12: 1758835920928635
Doi: 10.1177/1758835920928635
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Klocker, EV; Barth, DA; Riedl, JM; Prinz, F; Szkandera, J; Schlick, K; Kornprat, P; Lackner, K; Lindenmann, J; Stöger, H; Stotz, M; Gerger, A; Pichler, M
Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients.
Cancers (Basel). 2020; 12(5):
Doi: 10.3390/cancers12051154
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Klöckl, MC; Kasparek, AK; Riedl, JM; Moik, F; Mollnar, S; Stotz, M; Szkandera, J; Terbuch, A; Gerger, A; Niedrist, T; Pichler, M; Bauernhofer, T; Schilcher, G; Zitta, S; Rosenkranz, AR; Friedl, C; Stöger, H; Posch, F
Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy.
Sci Rep. 2020; 10(1):11219
Doi: 10.1038/s41598-020-68010-5
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Perakis, SO; Weber, S; Zhou, Q; Graf, R; Hojas, S; Riedl, JM; Gerger, A; Dandachi, N; Balic, M; Hoefler, G; Schuuring, E; Groen, HJM; Geigl, JB; Heitzer, E; Speicher, MR
Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer.
ESMO Open. 2020; 5(5):e000872
Doi: 10.1136/esmoopen-2020-000872
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Barth, DA; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoeger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Posch, F
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Cancers (Basel). 2020; 12(8):
Doi: 10.3390/cancers12082319
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Posch, F; Prager, G; Eisterer, W; Oehler, L; Sliwa, T; Wilthoner, K; Petzer, A; Pichler, P; Hubmann, E; Winder, T; Burgstaller, S; Korger, M; Andel, J; Greil, R; Neumann, HJ; Pecherstorfer, M; Philipp-Abbrederis, K; Djanani, A; Gruenberger, B; Laengle, F; Wöll, E; Gerger, A
The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.
Ther Adv Med Oncol. 2020; 12: 1758835919900872-1758835919900872.
Doi: 10.1177/1758835919900872
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Smolle, MA; Sande, MV; Callegaro, D; Wunder, J; Hayes, A; Leitner, L; Bergovec, M; Tunn, PU; van Praag, V; Fiocco, M; Panotopoulos, J; Willegger, M; Windhager, R; Dijkstra, SPD; van Houdt, WJ; Riedl, JM; Stotz, M; Gerger, A; Pichler, M; Stöger, H; Liegl-Atzwanger, B; Smolle, J; Andreou, D; Leithner, A; Gronchi, A; Haas, RL; Szkandera, J
Individualizing Follow-Up Strategies in High-Grade Soft Tissue Sarcoma with Flexible Parametric Competing Risk Regression Models.
Cancers (Basel). 2019; 12(1):
Doi: 10.3390/cancers12010047
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Stelzl, A; Aziz, F; Riedl, JM; Posch, F; Smolle, MA; Stojakovic, T; Terbuch, A; Pichler, M; Bergovec, M; Leithner, A; Liegl-Atzwanger, B; Stotz, M; Gerger, A; Sourij, H; Szkandera, J
Diabetes mellitus is independently associated with adverse clinical outcome in soft tissue sarcoma patients.
Sci Rep. 2020; 10(1): 12438-12438.
Doi: 10.1038/s41598-020-69237-y
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Stotz, M; Barth, DA; Riedl, JM; Asamer, E; Klocker, EV; Kornprat, P; Hutterer, GC; Prinz, F; Lackner, K; Stöger, H; Gerger, A; Pichler, M
The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer.
Cancers (Basel). 2020; 12(7):
Doi: 10.3390/cancers12071798
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Zhou, Q; Perakis, SO; Ulz, P; Mohan, S; Riedl, JM; Talakic, E; Lax, S; Tötsch, M; Hoefler, G; Bauernhofer, T; Pichler, M; Gerger, A; Geigl, JB; Heitzer, E; Speicher, MR
Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.
Genome Med. 2020; 12(1):20
Doi: 10.1186/s13073-020-0719-6
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Gerger, A; Riedl, JM; Perakis, S; Pregartner, G; Scheipner, L; Posch, F; Groller, K; Kashofer, K; Jahn, SW; Bauernhofer, T; Pichler, M; Stoger, H; Berghold, A; Hofler, G; Speicher, M; Heitzer, E
Profiling of circulating tumour DNA for treatment selection in patients with advanced and refractory carcinoma: A prospective, two-stage phase II individualized cancer treatment trial.
ANN ONCOL. 2020; 31: S1095-S1096.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.1331
[Onlinepräsentation]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
** Perakis, SO; Weber, S; Graf, R; Zhou, Q; Riedl, JM; Dandachi, N; Balic, M; Gerger, A; Schuuring, E; Groen, HJ; Geigl, JB; Speicher, MR; Heitzer, E
Identification of actionable targets in advanced cancer patients from circulating tumor DNA using clinical decision support platforms
CANCER RES. 2020; 80(16):-AACR Annual Meeting; JUN 22-24, 2020; ELECTR NETWORK.
Doi: 10.1158/1538-7445.AM2020-1315
[Poster]
Web of Science
FullText
FullText_MUG
** Posch, F; Barth, D; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Riedl, JM
C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: A bi-center study.
ANN ONCOL. 2020; 31: S286-S286.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.234
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
** Riedl, J; Perakis, S; Pregartner, G; Scheipner, L; Posch, F; Groller, K; Kashofer, K; Jahn, SW; Bauernhofer, T; Pichler, M; Stoger, H; Berghold, A; Hofler, G; Speicher, M; Heitzer, E; Gerger, A
Individualized cancer treatment based on molecular profiling of circulating tumor DNA in patients with advanced and refractory carcinoma: a prospective phase II trial.
ONCOL RES TREAT. 2020; 43(SUPPL 4):249-249.-DGHO Jahrestagung; 09.10. -11.10.2020; Basel (virtueller Kongress).
[Oral Communication]
Web of Science
** Riedl, J; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Schaberl-Moser, R; Stotz, M; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nab-Paclitaxel as palliative first-line treatment of advanced pancreatic cancer: An Austrian observational Tri-Center comparative effectiveness analysis.
ONCOL RES TREAT. 2020; 43(SUPPL 4):215-215.
[Poster]
Web of Science
** Riedl, JM; Posch, F; Gantschnigg, A; Horvath, L; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nabPaclitaxel as First-line palliative Therapy in advanced Pancreatic Cancer: a Propensity-Score Analysis.
WIEN KLIN WOCHENSCHR. Abstracts 51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin. 2020; 132(SUPPL 2):78-79.-51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; SEP 24-26, 2020; Salzburg, AUSTRIA.
[Poster]
Web of Science
** Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
ANN ONCOL. 2020; 31: S942-S942.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2013
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
** Schwarzenbacher, E; Moik, F; Horvath, L; Renneberg, F; Posch, F; Barth, D; Gantschnigg, A; Schaberl-Moser, R; Pichler, M; Stotz, M; Stoger, H; Ay, C; Greil, R; Gerger, A; Djanani, A; Schlick, K; Riedl, J
Incidence, prediction and outcome of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of Gemcitabine/nab-Paclitxel or FOLFIRINOX.
ONCOL RES TREAT. 2020; 43(SUPPL 4):214-214.
[Poster]
Web of Science
** Schwarzenbacher, E; Moik, F; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Ay, C; Stoger, H; Greil, R; Djanani, A; Gerger, A; Schlick, K; Riedl, JM
Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX.
ANN ONCOL. 2020; 31: S949-S950.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2035
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
2019
Originalarbeit (Zeitschrift)
** Barth, DA; Riedl, JM; Posch, F; Smolle, MA; Kasparek, AK; Niedrist, T; Szkandera, J; Stöger, H; Pichler, M; Stotz, M; Gerger, A
Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study.
Clin Transl Oncol. 2019; 21(8):1034-1043
Doi: 10.1007/s12094-019-02037-7
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Riedl, JM; Winder, T; Terbuch, A; Rossmann, CH; Szkandera, J; Bauernhofer, T; Kasparek, AK; Schaberl-Moser, R; Reicher, A; Prinz, F; Pichler, M; Stöger, H; Stotz, M; Gerger, A; Posch, F
Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis.
Sci Rep. 2019; 9(1):5548
Doi: 10.1038/s41598-019-42069-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Smolle, MA; van Praag, VM; Posch, F; Bergovec, M; Leitner, L; Friesenbichler, J; Heregger, R; Riedl, JM; Pichler, M; Gerger, A; Szkandera, J; Stöger, H; Smolle-Jüttner, FM; Liegl-Atzwanger, B; Fiocco, M; van de Sande, MA; Leithner, A
Surgery for metachronous metastasis of soft tissue sarcoma - A magnitude of benefit analysis using propensity score methods.
Eur J Surg Oncol. 2019; 45(2):242-248
Doi: 10.1016/j.ejso.2018.06.019
Web of Science
PubMed
FullText
FullText_MUG
** Terbuch, A; Posch, F; Bauernhofer, T; Pichler, M; Peinsith, H; Szkandera, J; Riedl, J; Hutterer, GC; Pummer, K; Partl, R; Kapp, KS; Stöger, H; Stotz, M; Gerger, A
Age as a Predictor of Treatment Outcome in Metastatic Testicular Germ Cell Tumors.
Anticancer Res. 2019; 39(10):5589-5596
Doi: 10.21873/anticanres.13753
Web of Science
PubMed
FullText
FullText_MUG
Übersichtsarbeit
** Riedl, JM; Stotz, M; Gerger, A
Role of immune checkpoint inhibitors in gastrointestinal cancer treatment
MEMO-MAG EUR MED ONC. 2019; 12(1): 71-76.
Doi: 10.1007/s12254-019-0470-0
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
** Smolle, MA; Kashofer, K; Riedl, JM; Stotz, M; Gerger, A
Genetic Analysis Using a Gene Panel in 87 Caucasian Patients With Colorectal Cancer: Own Results and Review of Literature.
Anticancer Res. 2019; 39(2): 847-852.
Doi: 10.21873/anticanres.13184
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Aziz, F; Stelzl, A; Riedl, J; Smolle, M; Stojakovic, T; Posch, F; Terbuch, A; Pichler, M; Leithner, A; Stoger, H; Liegl-Atzwanger, B; Stotz, M; Gerger, A; Szkandera, J; Sourij, H
Diabetes is a predictor for survival in soft tissue sarcoma patients
WIEN KLIN WOCHENSCHR. 2019; 131(SUPPL 5):S477-S477.
[Poster]
Web of Science
** Aziz, F; Stelzl, A; Riedl, JM; Smolle, MA; Stojakovic, T; Posch, F; Terbuch, A; Pichler, M; Leithner, A; Stoger, H; Liegl-Atzwanger, B; Stotz, M; Gerger, A; Szkandera, J; Sourij, H
Association of serum glucose levels with disease free survival in soft tissue sarcoma patients
DIABETOLOGIA. 2019; 62: S562-S563.-55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD); SEP 16-20, 2019; Barcelona, SPAIN.
[Poster]
Web of Science
** Barth, DA; Riedl, JM; Foris, V; Posch, F; Mollnar, S; Stotz, M; Pichler, M; Stoger, H; Absenger, G; Olschewski, H; Gerger, A
External validation and longitudinal extension of the LIPI (lung immune prognostic index) for immunotherapy outcomes in advanced non-small cell lung cancer
ONCOL RES TREAT. 2019; 42: 108-108.
[Poster]
Web of Science
** Perakis, SO; Ulz, P; Riedl, JM; Scheipner, L; Kashofer, K; Hoefler, G; Geigl, JB; Speicher, MR; Heitzer, E; Gerger, A
Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma: A prospective, two-stage Phase II individualized cancer treatment study
CANCER RES. 2019; 79(13):-Annual Meeting of the American-Association-for-Cancer-Research (AACR); MAR 29-APR 03, 2019; Atlanta, GA.
Doi: 10.1158/1538-7445.AM2019-CT130
[Poster]
Web of Science
FullText
FullText_MUG
** Riedl, J; Posch, F; Prager, G; Eisterer, W; Ohler, L; Thamer, S; Wilthoner, K; Petzer, A; Pichler, P; Hubmann, E; Winder, T; Burgstaller, S; Korger, M; Andel, J; Greil, R; Pecherstorfer, M; Philipp-Abbrederis, K; Djanani, A; Gruenberger, B; Langle, F; Woll, E; Gerger, A
The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study
ANN ONCOL. 2019; 30: -European-Society-for-Medical-Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer; JUL 03-06, 2019; Barcelona, SPAIN.
Doi: 10.1093/annonc/mdz155.285
[Poster]
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Barth, D; Posch, F; Foris, V; Absenger, G; Mollnar, S; Pichler, M; Stotz, M; Stoger, H; Olschewski, H; Gerger, A
Longitudinal C-reactive protein (CRP) trajectories predict immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer
ONCOL RES TREAT. 2019; 42: 115-115.
[Poster]
Web of Science
** Riedl, JM; Barth, DA; Foris, V; Posch, F; Mollnar, S; Stotz, M; Pichler, M; Stoger, H; Absenger, G; Olschewski, H; Gerger, A
External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer
ANN ONCOL. 2019; 30: -44th Congress of the European-Society-for-Medical-Oncology (ESMO); SEP 27-OCT 01, 2019; Barcelona, SPAIN.
[Poster]
Web of Science
2018
Originalarbeit (Zeitschrift)
** Posch, F; Partl, R; Döller, C; Riedl, JM; Smolle, M; Leitner, L; Bergovec, M; Liegl-Atzwanger, B; Stotz, M; Bezan, A; Gerger, A; Pichler, M; Kapp, KS; Stöger, H; Leithner, A; Szkandera, J
Benefit of Adjuvant Radiotherapy for Local Control, Distant Metastasis, and Survival Outcomes in Patients with Localized Soft Tissue Sarcoma: Comparative Effectiveness Analysis of an Observational Cohort Study.
Ann Surg Oncol. 2018; 25(3):776-783
Doi: 10.1245/s10434-017-6080-3
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Posch, F; Silina, K; Leibl, S; Mündlein, A; Moch, H; Siebenhüner, A; Samaras, P; Riedl, J; Stotz, M; Szkandera, J; Stöger, H; Pichler, M; Stupp, R; van den Broek, M; Schraml, P; Gerger, A; Petrausch, U; Winder, T
Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer.
Oncoimmunology. 2018; 7(2):e1378844-e1378844
Doi: 10.1080/2162402X.2017.1378844
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Leithner, A; van Praag, V; Posch, F; Bergovec, M; Leitner, L; Friesenbichler, J; Heregger, R; Smolle-Juttner, FM; Fiocco, M; van de Sande, M; Riedl, J; Pichler, M; Gerger, A; Szkandera, J; Stoger, H; Liegl-Atzwanger, B; Smolle, MA
Efficacy of metastasectomy on survival in patients with metachronous soft tissue sarcoma-metastasis: Results of a bi-centre study including 135 patients
ANN ONCOL. Abstract Book of the 43rd ESMO Congress (ESMO 2018) 19–23 October 2018, Munich, Germany. 2018; 29(S8):-43rd ESMO Congress (ESMO); OCT 19-23, 2018; Munich, GERMANY.
[Poster]
Web of Science
** Nazari, PMS; Riedl, J; Preusser, M; Posch, F; Thaler, J; Marosi, C; Birner, P; Ricken, G; Hainfellner, JA; Pabinger, I; Ay, C
The combination of podoplanin expression levels and IDH1 mutation status predicts VTE risk in patients with brain tumors
THROMB RES. 2018; 164: S195-S195.-9th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC); APR 13-15, 2018; Bergamo, ITALY.
Doi: 10.1016/j.thromres.2018.02.038
[Oral Communication]
Web of Science
FullText
FullText_MUG
Abstract (Konferenzband)
** Klöckl, MC; Kasparek, AK; Riedl, J; Moik ,F; Mollnar, S; Stotz, M; Szkandera, J; Terbuch, A; Gerger, A; Niedrist, T; Pichler, M; Bauernhofer T; Stöger H; Posch, F
Estimated versus measured glomerular filtration rate to
evaluate kidney function in patients with cancer undergoing
cisplatin-based chemotherapy
Oncology Research
and Treatment . 2018; 41(Suppl4):224-224.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; SEP 28- OCT 2, 2018; Vienna, AUSTRIA. (ISBN: 978-3-318-06425-4 )
[Poster]
Web of Science
FullText
2017
Originalarbeit (Zeitschrift)
** Riedl, JM; Posch, F; Bezan, A; Szkandera, J; Smolle, MA; Winder, T; Rossmann, CH; Schaberl-Moser, R; Pichler, M; Stotz, M; Stöger, H; Gerger, A
Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study.
BMC Cancer. 2017; 17(1):415-415
Doi: 10.1186/s12885-017-3392-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Posch, F; Moik, F; Bezan, A; Szkandera, J; Smolle, MA; Kasparek, AK; Pichler, M; Stöger, H; Stotz, M; Gerger, A
Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting.
Oncotarget. 2017; 8(56):96048-96061
Doi: 10.18632/oncotarget.21647
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Stotz, M; Herzog, SA; Pichler, M; Smolle, M; Riedl, J; Rossmann, C; Bezan, A; Stöger, H; Renner, W; Berghold, A; Gerger, A
Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.
Anticancer Res. 2017; 37(4):2011-2018
Doi: 10.21873/anticanres.11545
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2016
Originalarbeit (Zeitschrift)
** Kainhofer, V; Smolle, MA; Szkandera, J; Liegl-Atzwanger, B; Maurer-Ertl, W; Gerger, A; Riedl, J; Leithner, A
The width of resection margins influences local recurrence in soft tissue sarcoma patients.
Eur J Surg Oncol. 2016; 42(6):899-906
Doi: 10.1016/j.ejso.2016.03.026
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Riedl, J; Posch, F; Stotz, M; Bezan, A; Winder, T; Schaberl-Moser, R; Pichler, M; Stoeger, H; Gerger, A
Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance
ANN ONCOL. 2016; 27: -41st Congress of the European-Society-for-Medical-Oncology (ESMO); OCT 07-11, 2016; Copenhagen, DENMARK.
Doi: 10.1093/annonc/mdw370.107
[Poster]
Web of Science
FullText
FullText_MUG
** Silina, K; Petrausch, U; Posch, F; Leibl, S; Mundlein, A; Moch, H; Siebenhuner, A; Stupp, R; Riedl, J; Pestalozzi, BC; Schraml, P; Gerger, A; Winder, T
Comprehensive molecular and immunological analysis to assess the tumor immune contexture in stage II and III colorectal cancer
ANN ONCOL. 2016; 27:
Doi: 10.1093/annonc/mdw393.12
Web of Science
FullText
FullText_MUG